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Teaching a module on clinical trial research for 
PharmD students in Nepal: My experiences  
 
 
 
 
 
 
 
  
 
Dear Editor, 
 
In mid-August 2011 Ms Rajani Shakya, Assistant Professor, 
Pharmacy,  Kathmandu  University  (KU),  Dhulikhel,  Nepal 
asked me to facilitate and teach a module on clinical trial 
research  for  the  Doctor  of  Pharmacy  (PharmD)  students.  
My experiences of facilitating a module will be of interest to 
other  facilitators  and  educators  who  can  learn  about  the 
challenges I faced, problems while conducting the module 
and how they were overcome.  
 
Clinical trial research, a new subject area in Nepal: Based 
on a number of reasons including the small pharmaceutical 
industry, phase I, II and III clinical trials of new drugs are 
rarely conducted in Nepal unlike, the clinical trials of already 
marketed drugs, such as those used for altitude sickness, 
which  are  occasionally  conducted  in  the  Everest  and 
Annapurna region.  
 
PharmD students and small group learning: I emphasised 
both  the  drug  development  process  and  the  clinical 
development process of a new drug during the module. The 
module  consisted  of  12  sessions  with  an  additional 
concluding  session  to  wrap  up  the  proceedings  and  to 
obtain student feedback (Table 1). I used small group-based 
activity sessions which I had previously successfully used in 
teaching undergraduate medical students and other adult 
learners in various workshops. The module was undertaken 
in the third semester of the three-year post-baccalaureate 
PharmD programme. The programme is open to students 
who  have  completed  a  four  year  Bachelor  of  Pharmacy 
(BPharm)  The  Clinical  Research  module  is  a  two  credits 
course with a minimum requirement of 32 contact hours in 
the form of sessions and assignments. The 13 post-graduate 
students were divided into two smaller groups.   
Venue  for  the  sessions:  The  sessions  were  held  at  the 
University’s School of Management campus in the Lalitpur 
district.  The venue provided small tables and chairs which 
could be easily moved around, as well as a white board. In 
addition  to  the  white  board,  the  students  also  used  flip 
charts and we had access to a LCD projector.  
 
Creating an online mailing group: Based on my successful 
experience  with  effectively  sharing  information  using  an 
online  mailing  group  with  undergraduate  medical  (MBBS) 
students,  I  also  created  an  online  mailing  group  for  the 
PharmD  students.  The  online  group  was  used  by  the 
students to submit their assignments and by the facilitator 
to share reading materials and other clinical trial research 
resources  (e.g.  free  internet-based  textbooks  related  to 
clinical trial research, and material from the United States 
Food and Drug Administration (USFDA) and the European 
Medicines Agency (EMA) sites among many others)   
 
Assignments  and  formative  assessment:  Both  group  and 
individual  assignments  were  used  during  the  module. 
Students  were  typically  given  a  week  to  complete  and 
submit their assignments which are shown in Table 2. Both 
formative  and  summative  assessments  were  carried  out 
during the module. The formative assessment tasks (worth 
40%)  evaluated  the  students’  attendance,  punctuality, 
participation,  presentation  skills  and  their  assignment 
submissions. Then at the end of the module, a 150 minute 
short  answer  examination  was  used  as  a  summative 
assessment  task  (worth  60%)  to  evaluate  the  students’ 
knowledge and understanding about clinical trials.   
 
Group work: A 10-15 minute group work activity was an 
important  part  of  each  two  hour  small  group  learning 
session. Important clinical trial issues discussed during these 
group work activities included: developing a protocol for a 
clinical trial; focusing on different parts of the protocol; and 
good clinical trial practice. Table 3 clearly outlines the group 
work  activities  conducted  during  the  different  sessions. 
Informal  feedback  obtained  from  students  indicated  that 
small  group  activities  contributed  substantially  to  the 
module.  
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Student feedback on the module: Student feedback about 
the  module  was  obtained  informally  at  the  end  of  the 
module.  Their  perceived  knowledge,  attitude  and  skills 
about different subject areas before and at the conclusion 
of  the  module  were  studied.  The  author  also  obtained 
structured written feedback at the end of each session. The 
feedback obtained will be used to further improve future 
sessions.  
 
Possible lessons for other clinical trial research educators: 
To the best of my knowledge this is the first time a clinical 
trial  research  module  has  been  taught  in  Nepal  for 
pharmacy students. Based on my experience, clinical trial 
research  training  modules  can  be  effectively  delivered  in 
small  group  activity-based  learning  sessions,  using  white 
boards, flip charts and the submission of both formative and 
summative assessment tasks. In addition, the availability of 
online  resources,  online  group  discussion  forums  and 
internet sites also contribute to this learning environment 
which  can  be  successfully  used  to  deliver  new  and 
innovative  programs  such  as  this  one  to  the  PharmD 
students.  
  
Sincerely, 
 
Dr. P. Ravi Shankar 
 
KIST Medical College 
Lalitpur, Nepal.  
 
 
 
 
 
  
Table 1: Different sessions conducted during the clinical trial research teaching module 
 
Session number  Topic  Learning objectives  
(At the end of the session the student will be able to ) 
One  Drug development process  Describe the different stages in the drug development process 
Explain lead optimisation and toxicity testing  
Two  Drug development process 
2 & Ethics 
List components of an Investigational New Drug (IND) application 
Recognise  the relationship between phases of drug development and 
clinical trials 
Understand ethics and its importance in clinical trial research 
Describe  the functions of Institutional Review Boards (IRBs)  
Recall  the guidelines of Nepal Health Research Council  
Three  Introduction to clinical trials  Provide a  brief history of clinical trials  
Understand the importance of randomization and masking in clinical 
trial research  
Recall  ethical issues, and data monitoring in clinical trials  
Describe the  general principles of clinical trials  
Recognise  different trial designs 
Four  Phase I studies and 
pharmacokinetics 
Relate human phase I clinical trial studies to animal studies 
Describe the selection process for  volunteers, how to obtain 
informed consent, where to conduct clinical trials and  what type of   Australasian Medical Journal [AMJ 2012, 5, 3, 204-212] 
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insurance is required for  phase I clinical trials 
Describe the  importance of medication dosing schedules  in phase I 
clinical trials  
Five  Postmarketing surveillance 
and phase IV studies 
Understand postmarketing surveillance  
Explain the relationship between clinical trials and drug safety  
Describe the spontaneous reporting of Adverse Drug Reactions (ADRs)  
Understand the difference between  case control and cohort studies 
Design an ADR reporting form 
Describe  parts of the protocol for clinical trial research 
Six  Ethical issues in clinical trial 
research 
Understand ethical principles for conducting  clinical trial research 
Describe  the process for obtaining  informed consent  
Design a participant informed consent form  
Describe  the role  of an institutional review board  
Discuss the  national guidelines for clinical trials 
Recognise  potential vulnerable groups in clinical trials 
Describe the responsibilities of different individuals involved in clinical 
trials   
Seven  Good clinical trial practice  Understand what is Good Clinical Practice (GCP)?  
Describe  initiatives towards GCP 
Familiarise themselves with  the World Health Organization (WHO) 
handbook on GCP and International Conference on Harmonization 
(ICH) on GCP 
Describe the  Case Record Forms (CRFs) 
Describe multicentric trials 
List the essential documents required for  clinical trials   
Eight  Responsibilities of various 
individuals in a clinical trial 
Describe the  responsibilities of the sponsor in terms of  
manufacturing, packaging, coding of investigational products and ADR 
reporting in clinical trials  
Describe the  responsibilities of the clinical trials investigators, 
monitors and  research associates   Australasian Medical Journal [AMJ 2012, 5, 3, 204-212] 
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Nine  Data management in clinical 
trial research 
Understand how data is generated during a clinical trial 
Have an overview of the data management process  
Understand the process of managing and tracking CRFs  
Describe  the steps required for data review and clarification  
Understand issues relevant to validation, data queries, query tracking 
and resolutions  
Understand the importance of quality assurance and archiving  
Ten  Drug regulatory 
environments in Nepal, 
India and certain developed 
nations  
Understand the historical background of drug regulation 
Have  an overview of the clinical trial regulations with reference to the 
European commission, the United Kingdom, Nepal, the United States, 
Japan, the European medicines agency, and the Central Drugs 
Standard Control Organization (CDSCO) of India 
Obtain information about the  control of clinical trials by regulators 
Describe the  end points in clinical research  
Eleven  Phase III clinical trials  Describe Phase III clinical trials under the headings of objectives, 
subtypes, study population and study design 
Understand the publication guidelines for clinical trials 
Describe the Institutional Review Board (IRB) clearance of the clinical 
trial protocol, monitoring of the clinical trial, initiation meeting and 
other issues relevant to  phase III clinical trials 
Twelve  Miscellaneous issues   Describe how to complete an Abbreviated New Drug Application 
(ANDA) application 
Describe the  components of a drug master file 
Recognise  the importance of type 1 and type 2 errors 
Understand how to conduct a systematic review and list the steps 
involved in undertaking one 
Describe the importance of confidentiality in clinical research 
Understand the relevance of ghost writing, and negative results in 
clinical trials  
Describe phase II clinical trials    Australasian Medical Journal [AMJ 2012, 5, 3, 204-212] 
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Thirteen  Concluding session  Present concept maps about the topics discussed during the module 
Describe the steps in translating knowledge into practice  
Carry out a Strength, Weakness, Opportunity, Threat (SWOT) analysis 
on clinical research in Nepal 
Reflect on the strengths and weaknesses of the module  
                    
Table 2: Group and individual assignments used during the module 
 
Group assignments  1)  What are the four ethical principles mentioned 
in the national ethical guidelines for health 
research in Nepal?  
How will you ensure these guidelines are 
followed in clinical trials?    (to be submitted 
within a week of completion of session three) 
2)  Group A – Prepare an outline protocol for a 
phase I clinical trial of a new drug for 
tuberculosis  
Group B – Prepare an outline protocol for a 
phase III clinical trial of a new anticancer drug. 
(to be submitted within a week of completion 
of session eleven) 
3)  On a chart paper prepare a concept map of the 
issues discussed during the module on clinical 
trial research (to be presented during session 
thirteen)  
 
Individual assignments  1)  Develop a protocol for conducting a phase I 
clinical trial study of a new antihypertensive at 
the Kathmandu University (to be submitted 
within a week of completion of session four) 
2)  Develop a protocol for conducting a phase I 
clinical trial study of a new antidiabetic drug at 
the Kathmandu University (to be submitted 
within a week of completion of session four) 
3)  List the essential documents to be made 
available before the phase I of the clinical trial 
commences. 
List the additional essential documents to be 
made available after completion or termination 
of the trial. (to be submitted within a week of 
completion of session seven) 
 
 
Table 3: Group activities used during different sessions  
 
Topic  Group activities  
Drug development  1)  Do you think medicines, in general, are expensive in Nepal?  
How does Nepal compare with other countries in terms of medicine 
costs? (5 minutes) 
2)  What toxicity tests should a new drug undergo during preclinical 
testing? (10 minutes) 
  Australasian Medical Journal [AMJ 2012, 5, 3, 204-212] 
 
209 
Drug development process 2 & 
Ethics 
1)  Prepare an outline IND application for a new drug developed from 
Yarshagumba to treat male impotence. (Group A) (15 minutes) 
Prepare an outline IND application for a new drug developed to 
treat typhoid fever.  (Group B) (15 minutes) 
2)  Kindly list the various points to be mentioned while completing an 
IND application. (10 minutes) 
3)  What ethical problems do you foresee while conducting clinical trial 
research in Nepal? (10 minutes)  
 
Introduction to clinical trials  1)  What systems of post-marketing surveillance are available in Nepal? 
How can these systems be strengthened? (10 minutes) 
 
Phase I studies and 
pharmacokinetics 
1)    Outline the steps for conducting a phase I study of a new NSAID 
(Group A)(10 minutes) 
2) Outline the steps for conducting a phase I study of a new antibiotic 
among healthy humans (Group B) (10 minutes) 
 
Postmarketing surveillance and 
phase IV studies 
1)  In your group design a spontaneous ADR reporting form for 
medicines in phase IV trials on one side of the flip chart (15 minutes) 
 
Ethical issues in clinical trial 
research 
1)  Group A: Design an informed consent form (patient participation 
consent form) for a pharmacokinetic study which involves drawing 
repeated blood samples at frequent intervals over a two day period 
Group B: Design an informed participant consent form for a study 
among college students to ascertain their attitudes towards 
premarital sex.  (15 minutes) 
2)  Identify ten vulnerable groups and justify why they are considered 
as vulnerable for purposes of participation in clinical trials (10 
minutes) 
 
Good clinical trial practice  1)  Group A Kindly read the ICH GCP, WHO GCP and CDSCO GCP 
guidelines and define fifteen terms beginning with the letters from 
A to I 
Group B  Kindly read the ICH GCP, WHO GCP and CDSCO GCP 
guidelines and define 15 terms beginning with the letters from J to Z 
(15 minutes) 
2)  Group A: Referring to the WHO handbook answer the following 
questions: 
•  What types of changes may require formal amendment of the 
protocol for all phases of a clinical trial? 
•  When is unblinding of the trial by the investigator permissible? How 
should unblinding be accomplished (in those situations where it 
would be allowed)? 
•  Who is responsible for determining that the risk/benefit profile of a 
clinical trial study is acceptable or unacceptable? 
Group B: Referring to the WHO handbook answer the following 
questions: 
•  How is compliance with the protocol ensured and documented 
within GCP? 
•  How should serious unexpected adverse events (SAEs) be reported 
during phase I and phase II studies and to whom? 
•  What should be done if the benefit-risk profile of a study becomes 
unfavourable? (15 minutes) 
 
Responsibilities of various 
individuals in a clinical trial 
1)  Using the ICH GCP guidelines list the responsibilities of monitors of 
clinical trials (Group A)(15 minutes) 
Using the ICH GCP guidelines list the responsibilities of AUDITORS of 
clinical trials (Group B) (15 minutes) 
2)  Group A: Can you start a Contract Research Organization (CRO) in 
Nepal? If yes, how will you ensure the CRO is financially viable?   Australasian Medical Journal [AMJ 2012, 5, 3, 204-212] 
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Group B: Why are few clinical trials being conducted in Nepal? How 
could you ensure more clinical trial research is conducted in the 
country? (10 minutes) 
 
Data management in clinical trial 
research 
1)  What are the common problems with data that may arise at the 
entry stage? (5 minutes) 
 
Drug regulatory environments  1)  How can regulators exert control over clinical trials? (15 minutes) 
Phase III clinical trials  1)  Group A – Create an outline proposal for conducting a multicentric 
phase III study of a new antidiabetic drug in Nepal.  (10 minutes) 
Group B- Create an outline proposal for conducting a multicentric 
phase III study of a new anticancer drug in Nepal.  
 
Miscellaneous issues  There were no group activities during this phase. There was a 
presentation by a student on her home assignment on ghost writing 
and negative results in clinical trials. Students also presented an 
outline of their completed group assignments.    
Concluding session  1)  SWOT analysis of the clinical trial research scenario in Nepal  
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Audio files enhance classroom learning among 
medical students in Oman 
 
 
 
 
 
 
 
Dear Editor, 
 
The  students  at  Oman  Medical  College  (OMC)  are  mostly 
Arabic speaking, with English as the medium of instruction at 
college  and  university.  Since  the  curriculum  at  OMC  is 
designed in the Western style and faculty from US lecture for 
a variety of courses, a good knowledge of English is essential. 
A  variety  of  learning  styles  have  previously  been  described 
and studied, with research  demonstrating that the medium 
through  which  course  content  is  disseminated  may  impact 
learning.
1 Hence, complete understanding of lecture material 
presented  in  English  may  become  difficult  for  many  of  the 
students. Audio recordings of lecture material which can be 
accessed through the internet or downloaded to a portable 
media  player,  have  been  suggested  to  be  'an  educational 
revolution  in  the  making’.
2  In  December  2005,  Harvard 
became the first medical school to make its whole syllabus of 
lectures  downloadable  as  MP3/4  files  on  the  university 
intranet.
3  Listening  to  audio  files  of  course  material  helped 
students  improve  their  grades.
4  We  therefore  decided  to 
make use of this educational tool to enhance understanding 
and learning of course material in medical pharmacology. 
 
Audio recording of the lecture material using a Philips MP3 
recorder was performed during regular lecture sessions and 
students were encouraged to listen to them. The file in MP3 
format was then uploaded to the online site available to the 
students to access course material. The students downloaded 
them to an MP3 player or directly listened to them on their 
laptops. At the end of eight months of training an objective 
structured  questionnaire  was  prepared  to  assess  the 
effectiveness of usage of audio files. The questionnaire had 
close-ended  questions  as  well  as  questions  with  options 
“strongly  agree”  to  “strongly  disagree”.  All  students  who 
attended  pharmacology  lectures  took  part  in  the  survey. 
Results were compiled and analysed.  
 
Eighty  out  of  110  students  (77%)  responded  to  the  survey.  
49/80 (62%) agreed that they used these audio recordings to 
enhance their understanding of the material in pharmacology.  
A  high  proportion  of  the  students  (83%)  used  their  own 
laptops  to  listen  to  these  and  10%  of  the  students 
downloaded them to a mobile phone or an MP3 player.  While 
14%  of  the  students  listened  to  all  the  lectures,  a 
significant  number  (83%)  listened  to  selected  lectures 
only. Lack of time was a factor for not listening to the 
lecture in its entirety.  
 
Figure 1: Pie-chart showing when the students listened 
to the recordings 
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Regarding the period during which the students listened 
to the lectures, 18% listened to them on the same day of 
the lecture, 18% accessed them just before an exam and 
39% of the students accessed them within seven days of 
the  lecture.  The  remaining  25%  listened  to  them 
whenever they liked (Figure 1).  When asked how many 
times  they  accessed  the  files,  60%  listened  only  once 
while 29% listened to them two or three times and a small 
number of students (11%) listened to them several times 
to understand the material. Of the students 84% agreed 
that  listening  to  audio  recordings  helped  them  to 
understand and learn the lecture material in detail (Figure 
2). A further 76% of the students indicated that listening 
to  the  recordings  improved  their  understanding  of 
medical  terminologies  and  their  language  in  general. 
Moreover 44% of the students who used the recordings 
agreed that repeated listening was necessary to enhance 
their overall knowledge of the subject. The majority of the 
students  46/49  (94%)  who  listened  to  these  files 
recommended usage of this learning tool in other courses 
also (Figure 3). There were 38% of students who did not 
use the audio recordings and they had various reasons for 
not doing so. The major factors responsible were lack of 
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time  (60%)
1,2  and  23%  were  happy  with  the  clarity  of  the 
lectures  that  they  did  not  have  to  listen  to  the  audio 
recordings.  
 
Figure  2:  Student  opinion  on  whether  listening  to  audio 
recordings has helped them understand the lecture material 
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Figure 3: Student opinion on whether audio files should be 
made available for other courses 
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In  order  to  fully  understand  the  potential  value  of  audio 
recordings  as  a  supplementary  learning  tool  a  detailed 
understanding of students' experiences with the use of audio 
recordings is required. As medical educators, it is important in 
the context of a demanding curriculum to provide alternative 
resources and a supportive academic environment to facilitate 
individual  success.  This  is  especially  true  in  this  situation 
where  the  educational  and  cultural  background  is  very 
different  from  the  West.  Furthermore,  the  medium  of 
instruction  and  language  also  differs  from  that  which  is 
familiar and comfortable for this group of students.  
Our  findings  are  similar  to  reports  mentioned  in  the 
literature.
1 The use of audio recordings of lecture material 
has definitely improved understanding and learning the 
pharmacology subject in this small group of students. In 
future it is worth studying the value of this tool in a larger 
population to define a relationship between  the use of 
this educational tool and performance in assessments.   
 
 
Sincerely, 
 
Bindu Susan Varghese
1, Geener John
2 
 
1Assistant Professor, Department of Pharmacology. 
2 Assistant Professor, Department of Pathology and 
Medical Education. 
 Oman Medical College, Sohar, Sultanate of Oman. 
 
 
References 
1. Whitney ER and Pessina MA. Does Availability of Audio 
Podcasts Enhance the Classroom Experience for First Year 
Dental Students? Data on use and perceived benefits.  Int 
J Instr Tech and Dist learning 2008; 5(8): 27- 32. 
2.  Meade  O,  Bowskill  D  and  Lymn  JS.  Pharmacology 
podcasts: a qualitative study of non-medical prescribing 
students' use, perceptions and impact on learning. BMC 
Med Educ 2011; 11:2. 
3.  Rainsbury  JW  and  Mc  donnell  SM.  Podcasts:  an 
educational revolution in the making? J R Soc Med 2006; 
99(9): 481-82. 
4.  Kardong-Edgren  S  and  Emerson  R.  Student  adoption 
and  perception  of  lecture  podcasts  in  undergraduate 
bachelor of science in nursing courses. J Nurs Educ 2010; 
49(7):398-401. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 